# Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

> **NCT05664919** · NA · UNKNOWN · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 7000 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SA58 Nasal Spray

## Key facts

- **NCT ID:** NCT05664919
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 7000 (ESTIMATED)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664919, "Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05664919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*